CRVO heads into Tuesday's Q1 earnings call with the stock down 13% on the month, a just-released EPS miss already on the tape, and short sellers quietly adding exposure for the past six weeks.
The catalyst for Friday's 8.5% sell-off was an earnings miss filed after Thursday's close. Q1 EPS came in at -$0.86, missing the consensus estimate of -$0.78. The stock closed at $3.44 and is down nearly 13% on the week — close to its lowest levels in months. The formal results call is scheduled for May 19, where management will address the miss and provide any update on the Neflamapimod Phase 3 enrollment timeline.
Short positioning has been building steadily since mid-April, and the pace has picked up. Short interest is now 3.4% of the free float, a level that looks modest in isolation but reflects a 47% jump in shares sold short over the past month. The borrow market is tight-but-loosening: cost to borrow has eased from around 11% in early April to 8.4%, while availability has shifted meaningfully in recent sessions. The lending pool sat at full utilization — 100% of available shares lent out — on five separate days over the past two weeks, though it relaxed to 67% on May 14. That kind of oscillation between fully-lent and partially-lent conditions points to a thin, active borrow market where supply gets absorbed quickly when demand picks up.
The Street has stayed loyal, but quietly. All recent analyst actions have been reiterations of existing Buy ratings — HC Wainwright held at $25 in late April, D. Boral Capital has maintained a $31 target through multiple check-ins. No firm has downgraded. Yet the mean price target of roughly $22 reflects a wide range of views on a stock trading at $3.44, and that gap warrants a note of caution: these targets span biotech-style binary outcomes and are best read as directional conviction rather than precise valuation anchors. The bull case rests entirely on Neflamapimod data for dementia with Lewy bodies; the bear case is that pivotal trial enrollment runs through late 2027 and top-line data doesn't arrive until the second half of 2028, leaving a long cash-burn runway with limited near-term catalysts.
Past earnings reactions have been mixed but skewed negative. The March 17 update produced a 1-day move of -1.6% and a 5-day follow-through of -9.1%. A separate March 13 event saw a similar drift: flat on the day, -7.2% over the following week. The one positive outlier was November 2025, when the stock gained 4% the next day and 23.6% over five sessions — almost certainly driven by positive Neflamapimod data rather than the financial results themselves.
With the formal call on May 19, the focus is less on quarterly cash burn and more on any updated enrollment numbers or data timelines for the Lewy body trial — the variable the whole thesis turns on.
See the live data behind this article on ORTEX.
Open CRVO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
